Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology June 10, 2019 - NASDAQ Companies 0 » View More News for June 10, 2019